Shamburg News · 8-K filed Nov 9, 2026, 9:04 AM EST
Veradermics Reports 12-Month Positive Topline Data from Study '302' Part B for VDPHL01
MANE · Veradermics, Inc
- Other event
- Reg FD disclosure
- Materiality: high
On November 9, 2026, Veradermics, Incorporated announced positive 12-month topline results from Part B of its Phase 2/3 Study '302' evaluating VDPHL01 in over 500 males with mild-to-moderate pattern hair loss. In the VDPHL01 continued group, non-vellus hair count increased 43.9 hairs/cm2 (BID) and 29.7 hairs/cm2 (QD) from baseline to Month 12, and no new safety signals were observed. The information was furnished under Item 7.01 and Item 8.01 with a press release and investor presentation as Exhibits 99.1 and 99.2.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001827635-26-000038.
Written from the filing by Shamburg Markets. Figures are as reported by the company.